Prolysis Raises $9.9 Million to Fund Preclinical Development

Prolysis a private company focused on the discovery and development of novel antibiotic therapies, announced that it has raised US$9.9 million in a series B private equity financing. The fundraising was led by existing institutional investors and was joined by Fujisawa Investments for Entrepreneurs, L.P. ("FITE") and Fujisawa Investments for Entrepreneurs II, L.P. ("FITE II") investment arms of the Japanese pharmaceutical company Astellas Pharma Inc. for start-up bioventures.

()a href="http://www.bioportfolio.com/news/Prolysis_6.htm" target="_blank">BioPortfolio